| Q64233512 | A novel role for myeloid endothelin-B receptors in hypertension |
| Q92228425 | Absent or diminished pedal pulses and estimated GFR decline in patients with diabetic kidney disease |
| Q42429837 | Arrestin(g) podocyte injury with endothelin antagonism |
| Q27024623 | Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease |
| Q41522985 | Associations of genetic variants of endothelin with cardiovascular complications in patients with renal failure |
| Q37081787 | Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective |
| Q47248876 | Biomarkers of Endothelial, Renal, and Platelet Dysfunction in Stage 5 Chronic Kidney Disease Hemodialysis Patients With Heart Failure. |
| Q33561710 | CKD associates with cognitive decline |
| Q38248855 | Challenges and opportunities in the development of therapeutics for chronic kidney disease |
| Q38312509 | Chinese herbal medicine Shenqi Detoxification Granule inhibits fibrosis in adenine induced chronic renal failure rats |
| Q37469215 | Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. |
| Q38016491 | Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications |
| Q34167837 | Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). |
| Q38087529 | Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options |
| Q36850193 | Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis? |
| Q37775819 | Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension |
| Q37190271 | Deficiency in Six2 during prenatal development is associated with reduced nephron number, chronic renal failure, and hypertension in Br/+ adult mice |
| Q84601303 | Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy |
| Q46091583 | Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects |
| Q35019587 | ET-1 increases reactive oxygen species following hypoxia and high-salt diet in the mouse glomerulus |
| Q34420383 | Emerging drugs for chronic kidney disease |
| Q26767156 | Endothelin |
| Q43237868 | Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency. |
| Q92612738 | Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease |
| Q35050553 | Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy |
| Q37425654 | Endothelin receptor antagonists: status and learning 20 years on. |
| Q37119359 | Endothelin-1 and hypertension: from bench to bedside |
| Q36619734 | Endothelin-1 and the kidney--beyond BP. |
| Q34195357 | Endothelin-1 response to glucose and insulin among African Americans |
| Q36509293 | Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. |
| Q35120667 | Endothelin. |
| Q64443714 | Endothelins in cardiovascular biology and therapeutics |
| Q36717704 | Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography in patients with end-stage renal disease on dialysis therapy |
| Q38784727 | First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis |
| Q39685882 | G Protein-Coupled Receptor-G-Protein βγ-Subunit Signaling Mediates Renal Dysfunction and Fibrosis in Heart Failure. |
| Q30248872 | Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease |
| Q39503280 | Human recombinant erythropoietin alters the flow-dependent vasodilatation of in vitro perfused rat mesenteric arteries with unbalanced endothelial endothelin-1 / nitric oxide ratio |
| Q37813472 | Hypertension, left ventricular hypertrophy and chronic kidney disease |
| Q36659235 | Impact of endothelin A receptor antagonist selectivity in chronic nitric oxide synthase inhibition-induced fetal growth restriction in the rat. |
| Q43167304 | Increased ET-1 and reduced ET(B) receptor expression in uremic hypertensive rats |
| Q44777395 | Influence of endothelin-1 and nitric oxide on left ventricular remodelling in patients on peritoneal dialysis |
| Q59799492 | Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury |
| Q54424680 | Interaction of endothelin-1 and nitric oxide pathways in human tubular epithelial cells under the influence of cyclosporine-A. |
| Q36844501 | Interleukin-1beta, but not interleukin-6, enhances renal and systemic endothelin production in vivo |
| Q48371951 | Lower glomerular filtration rate associated with white matter hyperintensities more in vascular dementia than in Alzheimer's disease |
| Q64269252 | Management of Hypertension in Chronic Kidney Disease |
| Q41815253 | Methylglyoxal activates nociceptors through transient receptor potential channel A1 (TRPA1): a possible mechanism of metabolic neuropathies |
| Q37045219 | Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium |
| Q38201504 | New therapeutic strategies under development to halt the progression of renal failure |
| Q37219043 | Novel drugs and intervention strategies for the treatment of chronic kidney disease |
| Q34213510 | Plasma C-terminal pro-endothelin-1 is associated with target-organ damage in African Americans with hypertension |
| Q35354175 | Plasma pro-endothelin-1 peptide concentrations rise in chronic kidney disease and following selective endothelin A receptor antagonism |
| Q38186986 | Potential approaches to reverse or repair renal fibrosis |
| Q37599644 | Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure |
| Q35026662 | Potential renovascular hypertension, space missions, and the role of magnesium |
| Q37589007 | Primary hypertension and special aspects of hypertension in older children and adolescents |
| Q36016552 | Pulmonary hypertension complicating multiple myeloma |
| Q38112261 | Pulmonary hypertension in patients with chronic and end-stage kidney disease |
| Q26996772 | Pulmonary hypertension in renal disease: epidemiology, potential mechanisms and implications |
| Q92724115 | Role of the COP9 Signalosome (CSN) in Cardiovascular Diseases |
| Q35972212 | Sildenafil improves renal function in patients with pulmonary arterial hypertension |
| Q55378110 | Skeletal vascular perfusion is altered in chronic kidney disease. |
| Q89539962 | The Role of Endothelin and Endothelin Antagonists in Chronic Kidney Disease |
| Q36958430 | The cardiovascular physiology and pharmacology of endothelin-1. |
| Q36510011 | The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? |
| Q36379892 | The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment |
| Q46709379 | The road from AKI to CKD: the role of endothelin |
| Q38678678 | Therapeutic potential of endothelin receptor antagonism in kidney disease |
| Q27694623 | Treatment of chronic kidney disease |
| Q89550665 | Unfavorable Reduction in the Ratio of Endothelin B to A Receptors in Experimental 5/6 Nephrectomy and Adenine Models of Chronic Renal Insufficiency |
| Q38478059 | Update on glycemic control for the treatment of diabetic kidney disease. |
| Q36514906 | Uremic Toxicity of Advanced Glycation End Products in CKD. |
| Q37216920 | Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis |
| Q33364920 | Urinary protein profiling with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry in ETB receptor-deficient rats |
| Q38966893 | Why Is Your Patient Still Short of Breath? Understanding the Complex Pathophysiology of Dyspnea in Chronic Kidney Disease |
| Q47929318 | X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog |